Spruce Biosciences, Inc. (SPRB) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts SPRB Hot Sheet
Join SI Premium – FREE
Spruce Biosciences, Inc. (NASDAQ: SPRB) reported Q2 EPS of ($0.32), $0.07 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $750 thousand.
For earnings history and earnings-related data on Spruce Biosciences, Inc. (SPRB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta's capital-raising plans expose a major weakness in the AI boom
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
- First Hawaiian (FHB) Misses Q3 EPS by 7c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
